NZ530985A - Bv8 nucleic acids and polypeptides with mitogenic activity - Google Patents
Bv8 nucleic acids and polypeptides with mitogenic activityInfo
- Publication number
- NZ530985A NZ530985A NZ530985A NZ53098502A NZ530985A NZ 530985 A NZ530985 A NZ 530985A NZ 530985 A NZ530985 A NZ 530985A NZ 53098502 A NZ53098502 A NZ 53098502A NZ 530985 A NZ530985 A NZ 530985A
- Authority
- NZ
- New Zealand
- Prior art keywords
- endothelial cells
- polypeptides
- medicament
- nucleic acids
- mitogenic activity
- Prior art date
Links
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 230000002297 mitogenic effect Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000035755 proliferation Effects 0.000 abstract 2
- 230000004083 survival effect Effects 0.000 abstract 2
- 208000005676 Adrenogenital syndrome Diseases 0.000 abstract 1
- 208000028060 Albright disease Diseases 0.000 abstract 1
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 206010058359 Hypogonadism Diseases 0.000 abstract 1
- 201000001853 McCune-Albright syndrome Diseases 0.000 abstract 1
- 208000026062 Tissue disease Diseases 0.000 abstract 1
- 239000003098 androgen Substances 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 201000003368 hypogonadotropic hypogonadism Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000000509 infertility Diseases 0.000 abstract 1
- 230000036512 infertility Effects 0.000 abstract 1
- 231100000535 infertility Toxicity 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000001061 polyostotic fibrous dysplasia Diseases 0.000 abstract 1
- 208000006155 precocious puberty Diseases 0.000 abstract 1
- 230000035938 sexual maturation Effects 0.000 abstract 1
- 230000000365 steroidogenetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5064—Endothelial cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31618401P | 2001-08-29 | 2001-08-29 | |
| PCT/US2002/027571 WO2003020892A2 (en) | 2001-08-29 | 2002-08-27 | Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ530985A true NZ530985A (en) | 2006-03-31 |
Family
ID=23227889
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ530985A NZ530985A (en) | 2001-08-29 | 2002-08-27 | Bv8 nucleic acids and polypeptides with mitogenic activity |
| NZ543755A NZ543755A (en) | 2001-08-29 | 2002-08-27 | Bv8 nucleic acids and polypeptides with mitogenic activity |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ543755A NZ543755A (en) | 2001-08-29 | 2002-08-27 | Bv8 nucleic acids and polypeptides with mitogenic activity |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US7060278B2 (https=) |
| EP (2) | EP1427830B1 (https=) |
| JP (1) | JP4361791B2 (https=) |
| KR (3) | KR100942880B1 (https=) |
| CN (2) | CN1575338B (https=) |
| AT (1) | ATE557092T1 (https=) |
| AU (1) | AU2002332732B2 (https=) |
| BR (1) | BR0212070A (https=) |
| CA (1) | CA2458670C (https=) |
| DK (1) | DK1427830T3 (https=) |
| ES (1) | ES2386346T3 (https=) |
| HU (1) | HU230373B1 (https=) |
| IL (4) | IL160422A0 (https=) |
| IS (1) | IS2889B (https=) |
| MX (1) | MXPA04001720A (https=) |
| NO (2) | NO332445B1 (https=) |
| NZ (2) | NZ530985A (https=) |
| PL (1) | PL368972A1 (https=) |
| SI (1) | SI1427830T1 (https=) |
| WO (1) | WO2003020892A2 (https=) |
| ZA (1) | ZA200401001B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL368972A1 (en) * | 2001-08-29 | 2005-04-04 | Genentech, Inc. | Bv8 nucleic acids and polypeptides with mitogenic activity |
| WO2003040326A2 (en) * | 2001-11-02 | 2003-05-15 | Nuvelo, Inc. | Methods and materials relating to prokineticin-like polypeptides and polynucleotides |
| JP4912144B2 (ja) * | 2003-03-12 | 2012-04-11 | ジェネンテック， インコーポレイテッド | 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用 |
| GB0320238D0 (en) | 2003-08-29 | 2003-10-01 | Medical Res Council | Treatment of disease |
| WO2005042717A2 (en) * | 2003-10-31 | 2005-05-12 | The Regents Of The University Of California | Primate prokineticin and prokineticin receptor polypeptides, related compositions and methods |
| EP1756153A2 (en) * | 2004-03-29 | 2007-02-28 | Janssen Pharmaceutica N.V. | Prokineticin 2beta peptide and its use |
| US7872430B2 (en) * | 2005-11-18 | 2011-01-18 | Cree, Inc. | Solid state lighting panels with variable voltage boost current sources |
| US20070243584A1 (en) * | 2006-04-13 | 2007-10-18 | West James W | Tetramerizing polypeptides and methods of use |
| US20100075377A1 (en) * | 2006-04-13 | 2010-03-25 | West James W | Tetramerizing polypeptides and methods of use |
| EP2004682A2 (en) * | 2006-04-13 | 2008-12-24 | Zymogenetics, Inc. | Tetramerizing polypeptides and methods of use |
| CL2008002782A1 (es) * | 2007-09-21 | 2009-07-31 | Genentech Inc | Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular. |
| KR101044874B1 (ko) * | 2008-12-02 | 2011-06-28 | 주식회사 동호 | 흡인식 쓰레기 설비의 이송관로 막힘 검출 시스템 |
| RU2559542C2 (ru) | 2009-12-23 | 2015-08-10 | Дженентек, Инк. | Антитела против bv8 и их применение |
| KR101040724B1 (ko) * | 2010-08-16 | 2011-06-10 | 주식회사 에스더블 테크 | 공기이송 더스트 배출장치 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4109496A (en) * | 1977-12-20 | 1978-08-29 | Norris Industries | Trapped key mechanism |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| EP0052322B1 (de) | 1980-11-10 | 1985-03-27 | Gersonde, Klaus, Prof. Dr. | Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| US4943529A (en) | 1982-05-19 | 1990-07-24 | Gist-Brocades Nv | Kluyveromyces as a host strain |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| AU3145184A (en) | 1983-08-16 | 1985-02-21 | Zymogenetics Inc. | High expression of foreign genes in schizosaccharomyces pombe |
| DE3483949D1 (de) | 1983-09-26 | 1991-02-21 | Udo Dr Med Ehrenfeld | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946783A (en) | 1987-01-30 | 1990-08-07 | President And Fellows Of Harvard College | Periplasmic protease mutants of Escherichia coli |
| US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
| IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
| GB8724885D0 (en) | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
| EP0321196A3 (en) | 1987-12-18 | 1990-07-18 | Mycogen Plant Science, Inc. | 780 t-dna gene transcription activator |
| ATE105585T1 (de) | 1987-12-21 | 1994-05-15 | Univ Toledo | Transformation von keimenden pflanzensamen mit hilfe von agrobacterium. |
| AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
| AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| US5240848A (en) * | 1988-11-21 | 1993-08-31 | Monsanto Company | Dna sequences encoding human vascular permeability factor having 189 amino acids |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| ATE144281T1 (de) | 1989-04-28 | 1996-11-15 | Rhein Biotech Proz & Prod Gmbh | Hefezellen der gattung-schwanniomyces |
| US5332671A (en) * | 1989-05-12 | 1994-07-26 | Genetech, Inc. | Production of vascular endothelial cell growth factor and DNA encoding same |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| DK168302B1 (da) | 1989-06-29 | 1994-03-07 | Danisco | Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller |
| FR2649120B1 (fr) | 1989-06-30 | 1994-01-28 | Cayla | Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede |
| ES2083469T3 (es) | 1989-11-22 | 1996-04-16 | Genentech Inc | Peptido asociado a una latencia y utilizaciones del mismo. |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5206161A (en) * | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
| US5605793A (en) * | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| AUPM425294A0 (en) * | 1994-03-04 | 1994-03-31 | Australian National University, The | In-vitro angiogenesis assay |
| US5561053A (en) | 1994-08-05 | 1996-10-01 | Genentech, Inc. | Method for selecting high-expressing host cells |
| US6013780A (en) | 1996-09-06 | 2000-01-11 | Technion Research & Development Co. Ltd. | VEGF145 expression vectors |
| US20020172678A1 (en) * | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
| EP1230362A2 (en) | 1999-11-16 | 2002-08-14 | ZymoGenetics, Inc. | Human zven proteins |
| WO2002036625A2 (en) * | 2000-11-03 | 2002-05-10 | The Regents Of The University Of California | Prokineticin polypeptides, related compositions and methods |
| PL368972A1 (en) * | 2001-08-29 | 2005-04-04 | Genentech, Inc. | Bv8 nucleic acids and polypeptides with mitogenic activity |
| JP4912144B2 (ja) | 2003-03-12 | 2012-04-11 | ジェネンテック， インコーポレイテッド | 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用 |
| CL2008002782A1 (es) * | 2007-09-21 | 2009-07-31 | Genentech Inc | Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular. |
-
2002
- 2002-08-27 PL PL02368972A patent/PL368972A1/xx not_active Application Discontinuation
- 2002-08-27 AU AU2002332732A patent/AU2002332732B2/en not_active Ceased
- 2002-08-27 WO PCT/US2002/027571 patent/WO2003020892A2/en not_active Ceased
- 2002-08-27 DK DK02797786.7T patent/DK1427830T3/da active
- 2002-08-27 KR KR1020047002640A patent/KR100942880B1/ko not_active Expired - Fee Related
- 2002-08-27 MX MXPA04001720A patent/MXPA04001720A/es active IP Right Grant
- 2002-08-27 ES ES02797786T patent/ES2386346T3/es not_active Expired - Lifetime
- 2002-08-27 IL IL16042202A patent/IL160422A0/xx unknown
- 2002-08-27 CN CN028209664A patent/CN1575338B/zh not_active Expired - Fee Related
- 2002-08-27 SI SI200230990T patent/SI1427830T1/sl unknown
- 2002-08-27 JP JP2003525596A patent/JP4361791B2/ja not_active Expired - Fee Related
- 2002-08-27 NZ NZ530985A patent/NZ530985A/xx not_active IP Right Cessation
- 2002-08-27 KR KR1020107002333A patent/KR101008785B1/ko not_active Expired - Fee Related
- 2002-08-27 KR KR1020097012101A patent/KR101008734B1/ko not_active Expired - Fee Related
- 2002-08-27 NZ NZ543755A patent/NZ543755A/en not_active IP Right Cessation
- 2002-08-27 CA CA2458670A patent/CA2458670C/en not_active Expired - Fee Related
- 2002-08-27 HU HU0401584A patent/HU230373B1/hu not_active IP Right Cessation
- 2002-08-27 US US10/231,411 patent/US7060278B2/en not_active Expired - Lifetime
- 2002-08-27 AT AT02797786T patent/ATE557092T1/de active
- 2002-08-27 BR BR0212070-4A patent/BR0212070A/pt not_active Application Discontinuation
- 2002-08-27 EP EP02797786A patent/EP1427830B1/en not_active Expired - Lifetime
- 2002-08-27 CN CN201010227537.3A patent/CN101884784B/zh not_active Expired - Fee Related
- 2002-08-27 EP EP10009859A patent/EP2311960A3/en not_active Withdrawn
-
2004
- 2004-02-06 ZA ZA200401001A patent/ZA200401001B/en unknown
- 2004-02-06 NO NO20040553A patent/NO332445B1/no not_active IP Right Cessation
- 2004-02-13 IS IS7154A patent/IS2889B/is unknown
- 2004-02-16 IL IL160422A patent/IL160422A/en not_active IP Right Cessation
-
2006
- 2006-03-17 US US11/384,222 patent/US20060204510A1/en not_active Abandoned
- 2006-09-29 US US11/536,880 patent/US7811984B2/en not_active Expired - Fee Related
-
2009
- 2009-03-11 IL IL197539A patent/IL197539A/en not_active IP Right Cessation
-
2010
- 2010-03-16 IL IL204543A patent/IL204543A/en not_active IP Right Cessation
-
2012
- 2012-05-24 NO NO20120612A patent/NO334713B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ530985A (en) | Bv8 nucleic acids and polypeptides with mitogenic activity | |
| DK0950096T3 (da) | Anti-invasive og anti-angiogene urokinase-fragmenter og deres anvendelse | |
| DK1265914T3 (da) | WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme | |
| AR018346A1 (es) | Peptidos mutantes promotores de la inmunidad celular t, composiciones farmaceuticas y vacunas formuladas con dichos peptidos para el tratamiento decanceres; uso de dichos peptidos, metodo para identificar dichos peptidos y secuencias de adn que codifican dichos peptidos mutantes y vectores y plasmid | |
| NZ512705A (en) | Gene therapy to promote angiogenesis | |
| WO2003035846A3 (en) | Structure of tall-1 and its cognate receptor | |
| TW581808B (en) | Compounds for immunotherapy of prostate cancer and methods for their use | |
| BR0009505A (pt) | Compostos e processos para terapia e diagnóstico de câncer de pulmão | |
| EP1409547A4 (en) | METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TREATING THE IMMUNE SYSTEM, IN PARTICULAR FOR USE IN CANCER THERAPY | |
| WO2006090810A3 (en) | Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides | |
| WO2004002418A3 (en) | Compositions and methods comprising protein activated receptor antagonists | |
| JP2005504532A5 (https=) | ||
| DE60238435D1 (de) | Gezielte thrombose durch gewebefaktor polypeptiden | |
| DE60143818D1 (de) | Alpha-fetoprotein-peptide und ihre verwendung | |
| MY141459A (en) | Recombinant anti-idiotypic antibodies | |
| NO20011537L (no) | Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes | |
| WO2003016342A3 (en) | Tumor antigens for prevention and/or treatment of cancer | |
| AU2001289034A1 (en) | Novel pdes and uses thereof | |
| WO2003093298A3 (en) | Immunogenic peptides | |
| UA83989C2 (ru) | Выделенный пептид, который стимулирует противоопухолевый иммунный ответ, фармацевтическая композиция на его основе и ее применение | |
| AU2003234342A8 (en) | Ablated slam-dependent entry | |
| Marotti et al. | The role of cytokines in MET-enkephalin-modulated nitric oxide release | |
| TW200517125A (en) | Pharmaceutical composition for treatment of solid cancers | |
| WO2006052775A3 (en) | Peptide anti - tumor agent | |
| DE60207103D1 (en) | Immunogene alk (anaplastic lymphoma kinase) peptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 AUG 2016 BY THOMSON REUTERS Effective date: 20150711 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 AUG 2017 BY THOMSON REUTERS Effective date: 20160714 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 AUG 2018 BY THOMSON REUTERS Effective date: 20170720 |
|
| LAPS | Patent lapsed |